CBMG To Acquire Agreen In All-China Deal
This article was originally published in PharmAsia News
Executive Summary
In an all-China deal, Cellular Biomedicine Group has agreed to pay $3.3 million in cash plus equity for Agreen Biotech China, which is developing technology and therapies for cancer and immune disorders.